New RNAi company Dicerna raises second series A
This article was originally published in Scrip
Executive Summary
A new RNAi company, Dicerna Pharmaceuticals, has raised an additional $8.4 million in venture capital bringing the total series A funds raised to $21.4 million. New investor Abingworth joined existing investors Oxford Bioscience and Skyline Ventures in the second closing.